Theradex Systems

The story of Theradex Oncology began in 1982, a pivotal year that marked its inception with a significant contract from the National Cancer Institute (NCI) in the United States. This foundational partnership, the Clinical Trials Monitoring Service, entrusted Theradex with the crucial responsibility of central data management and monitoring for early-phase cancer trials sponsored by the NCI. This early collaboration with a prestigious institution like the NCI set the stage for Theradex's evolution into a leading contract research organization (CRO) with a singular focus on oncology. The company's journey has been one of steady growth and expanding expertise, always keeping pace with the rapid advancements in cancer research and treatment. What started as a dedicated service to a national institute has since blossomed into a global operation, extending its comprehensive clinical trial services to the pharmaceutical industry worldwide.

Over the decades, Theradex has meticulously built a reputation for its deep scientific knowledge and personalized approach. The company's expansion into Europe in 1992 with the opening of Theradex (Europe) Ltd. was a significant milestone, enabling it to offer seamless, global trial support. This international presence has been further strengthened through strategic partnerships in other key regions, including Asia. Throughout its history, Theradex has remained at the forefront of innovation, integrating new technologies and methodologies to enhance the efficiency and effectiveness of the clinical trial process. The company's unwavering commitment to its mission—to ensure that new discoveries in cancer drug development have the best possible chance to benefit humanity—has been the driving force behind its success. From its early days supporting the NCI to its current status as a full-service global CRO, Theradex continues to play a vital role in the fight against cancer, helping to bring promising new treatments to patients around the world.